Global Opportunities

Partnership Opportunities for Swiss Pharmaceutical Companies in the Brazilian Market

The Brazilian pharmaceutical market is the sixth largest in the world, and despite the economic recession, it is expected to grow at a CAGR rate of 9-12% between 2016 and 2020, reaching USD 34bn-44bn according to IMS Health and EMIS.

Swiss pharmaceutical companies can enter the brazilian market with a local partnership

Entering this attractive but rather complex market is not easy, mainly for the bureaucracy of its regulatory health agency, ANVISA. However, a local partnership can be a good option for companies willing to take the first steps into the country without big investments. In this article, we present the profile of 6 companies looking for partnerships to bring new products to the Brazilian market.

The Brazilian pharmaceutical market is the sixth largest in the world and second only to China among emerging markets in terms of sales value. The domestic drug sales, based on ex-factory prices, more than doubled in size over the period 2010-2015, driven by growing public health expenditure and increasing household income. Despite the current economic recession, the long-term prospects for the pharmaceutical sector remain positive, with the expectation of a CAGR growth of 9-12% to reach USD 34bn-44bn between 2016 and 2020, according to IMS Health and EMIS.

For seizing these growth opportunities, local and international pharmaceutical players in Brazil are actively looking for new drugs to license and promote, not only in the country but also in the Latin American region.

The participation of the Swiss Business Hub Brazil team at an important matchmaking event in São Paulo for Business Developers in pharma companies on May 26th – the Pharma Meeting  – was a proof of this interest. Many interlocutors mentioned to be looking for high-quality, innovative products, and specifically addressed the SBH Brazil in order to reach Swiss companies willing to discuss local partnerships.

This can be a good option for companies that wish to explore this attractive market, but do not want to deal directly with the complexity of ANVISA, the Brazilian Health Surveillance Agency, and other local regulatory bodies.

Below, we summarize the contacts made during the Pharma Meeting event, and the opportunities presented to Swiss companies:

Sanofi/Medley –

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care.

In Brazil, strategic partnerships are one pillar to enhance the company’s Established and Generics product portfolio. For that reason, the company is looking for new products to market in in the Latin American region, in the following areas:

  • Gastrology
  • Cardiology
  • Central Nervous System
  • Women’s Health
  • Innovative OTC

Abbott –

Abbott arrived in Brazil in 1937, having its administrative headquarters in São Paulo and its plant in Jacarepaguá neighborhood, in Rio de Janeiro. It has about 1,400 employees across the country, working with the segments of Nutrition, Diagnostics, Vascular, Diabetes Care and Branded Generics.

The company is looking for new products to market in Brazil, in the following areas:

  • Women’s health
  • Gastrology
  • Musculoskeletal
  • Central Nervous System
  • Respiratory
  • Cardiology
  • Endocrinology

It is mandatory that the products have sound medical documentation, including all clinical studies.

Daiichi Sankyo –

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. The company provides innovative products and services in more than 20 countries around the world. In Brazil, Daiichi Sankyo is a medium-sized player and has a plant in the city of Barueri, close to São Paulo. They are looking manufacturers of innovative products interested in a potential partnership in Brazil and other Latin American countries, in order to increase their portfolio in the region.

The products of interest are:

  • Cardiology
  • Central Nervous System
  • Pain
  • Gastrology

Unither-Mariol –

UNITHER is a French company, specialized in BFS (Blow Fill Seal) for the pharmaceutical industry. UNITHER acquired the local plant of Mariol Industrial in Brazil in 2015, located in Barretos. The subsidiary is oriented in a 100% CMO activity, with a focus on liquid forms (syrups, suspensions), and the newly added stick-pack concept.

Unither-Mariol considers to be an industrial service provider for the pharmaceutical companies willing to manufacture locally, and is looking for new partners in the following therapeutical areas:

  • Drug delivers’ technology
  • Gastroenterology
  • Ophthalmology
  • Pain
  • Respiratory

Choice –

Choice is a Distributor of Medicines and Pharmaceutical Supplies with more than 43 years of experience in Brazil. The company has a raw-material plant in Argentina and has recently inaugurated an Oral Solids factory with focus in the Latin American markets. They are looking for new partners and/or customers in the following therapeutical areas:

  • Antibiotics
  • Diabetes
  • Hypertension
  • Central Nervous System

Masters Speciality Pharma –

Masters Speciality Pharma is a leading international pharmaceutical company with expertise in supplying advanced medicines to Hospitals, Pharmacists, Clinics and Governments as well as directly to individual patients (Named Patient Supply).

Present in Brazil since 2008, the company is looking for partners in different therapeutical areas that focus on Hospitals, Health Professionals and Government.

If you are a Swiss pharmaceutical company interested in any of the partnership opportunities presented above, please contact Switzerland Global Enterprise and the Swiss Business Hub Brazil teams for further information.

The next Country Consulting Week Brazil, to be held in Zürich, Basel and Lausanne from June 19th to June 23rd, can also be a good occasion to personally meet our team and receive more inputs about this attractive but rather complex market.



Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program